Sentences with phrase «biotechnology value fund»

Posted in Activist Investors, Biotechnology Value Fund, Greenbackd Portfolio, Net Cash Stocks, OrthoLogic Corporation (NASDAQ: CAPS), tagged Biotechnology Value Fund, Net Cash Stock, OrthoLogic Corporation (NASDAQ: CAPS) on February 27, 2009 2 Comments»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value, Net Cash Stock on August 24, 2009 1 Comment»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value, Net Cash Stock 1 Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management on April 13, 2009 Leave a Comment»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock Leave a Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management, Dolphin Limited Partnership, GAMCO, Icagen Inc (NASDAQ: ICGN), Mill Road Capital, Multimedia Games Inc (NASDAQ: MGAM), Nery Capital Partners, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management, InFocus Corporation (NASDAQ: INFS), Kona Grill Inc (NASDAQ: KONA), Multimedia Games Inc (NASDAQ: MGAM), Nery Capital Partners on February 10, 2009 Leave a Comment»

Posted in Activist Investors, Biotechnology Value Fund, Net Cash Stocks, OrthoLogic Corporation (NASDAQ: CAPS) Tagged Biotechnology Value Fund, Net Cash Stock, OrthoLogic Corporation (NASDAQ: CAPS) Leave a Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Greenbackd Portfolio, Liquidation Value, Net Cash Stocks, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value, Net Cash Stock on July 21, 2009 Leave a Comment»

While it trades below its net cash value and Biotechnology Value Fund (BVF) has disclosed a 13.42 % holding, BVF's holding is passive.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Neurobiological Technologies Inc (NASDAQ: NTII), Northstar Neuroscience Inc (NASDAQ: NSTR), Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Neurobiological Technologies Inc (NASDAQ: NTII), Northstar Neuroscience Inc (NASDAQ: NSTR), RA Capital Management on March 11, 2009 Leave a Comment»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management, Dolphin Limited Partnership, GAMCO, Icagen Inc (NASDAQ: ICGN), Mill Road Capital, Multimedia Games Inc (NASDAQ: MGAM), Nery Capital Partners, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, CuraGen Corporation (NASDAQ: CRGN), DellaCamera Capital Management, InFocus Corporation (NASDAQ: INFS), Kona Grill Inc (NASDAQ: KONA), Multimedia Games Inc (NASDAQ: MGAM), Nery Capital Partners Leave a Comment

Posted in Activist Investors, Biotechnology Value Fund, Net Cash Stocks, OrthoLogic Corporation (NASDAQ: CAPS), tagged Biotechnology Value Fund, Net Cash Stock, OrthoLogic Corporation (NASDAQ: CAPS) on March 16, 2009 Leave a Comment»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, InFocus Corporation (NASDAQ: INFS), Kona Grill Inc (NASDAQ: KONA), MathStar Inc (OTC: MATH), Mill Road Capital, Nery Capital Partners, Salvatore Muoio, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, InFocus Corporation (NASDAQ: INFS), Kona Grill Inc (NASDAQ: KONA), MathStar Inc (OTC: MATH), Mill Road Capital, S. Muoio & Co, Salvatore Muoio on January 7, 2009 Leave a Comment»

We started following CAPS (see our post archive here) because it was trading below its net cash value and Biotechnology Value Fund (BVF) had a 13.42 % holding.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value, Net Cash Stock on August 27, 2009 Leave a Comment»

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock 1 Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock 2 Comments

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Neurobiological Technologies Inc (NASDAQ: NTII), Northstar Neuroscience Inc (NASDAQ: NSTR), Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Neurobiological Technologies Inc (NASDAQ: NTII), Northstar Neuroscience Inc (NASDAQ: NSTR), RA Capital Management Leave a Comment

Wes Gray's Empirical Search Strategies (ESS) has proclaimed its support for a «downside protection» measure described by the Biotechnology Value Fund (BVF) in the Avigen Inc (NASDAQ: AVGN) proxy fight.

The Biotechnology Value Fund, often called BVF, was a longtime shareholder in Avigen.

Posted in Biotechnology Value Fund, Net Cash Stocks, OrthoLogic Corporation (NASDAQ: CAPS), Stocks Tagged Biotechnology Value Fund, Net Cash Stock, OrthoLogic Corporation (NASDAQ: CAPS) Leave a Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value, Net Cash Stock Leave a Comment

(«ESS»), the beneficial owner of approximately 2.3 % of the Avigen, Inc.'s (Nasdaq: AVGN — News) outstanding common stock, has proclaimed their support for a «downside protection» measure described by the Biotechnology Value Fund («BVF»).

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value on May 22, 2009 2 Comments»

The first is the clash between Avigen Inc (Nasdaq: AVGN) and Biotechnology Value Fund (BVF).

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidation Value Leave a Comment

NEW YORK, March 6, 2009 — BVF Acquisition LLC (the «Purchaser»), an affiliate of Biotechnology Value Fund L.P. («BVF»), which has commenced a cash tender offer to purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: AVGN)(«Avigen») for $ 1.00 per share, announced today that it has extended the expiration date for the tender offer to 6:00 p.m., New York City time, on Friday, April 3, 2009.

We've been following AVGN (see archived posts here) because it's a net cash stock (i.e. it's trading at less than the value of its cash after deducting all liabilities) and specialist biotechnology investor Biotechnology Value Fund (BVF) has been pushing it to liquidate and return its cash to shareholders.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Net Net Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock Leave a Comment

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock Leave a Comment

Biotechnology Value Fund (BVF) responded on Friday to Avigen, Inc.'s (NASDAQ: AVGN) announcement that its board is «considering «strategic alternatives,»» announcing that it...

Biotechnology Value Fund (BVF) has extended its tender offer for the outstanding shares of Avigen Inc (Nasdaq: AVGN).

Avigen Inc (NASDAQ: AVGN) has authorized its CEO, Dr. Chahine, and RBC to contact Biotechnology Value Fund (BVF) to explore the possibility of negotiating a settlement between BVF and AVGN with respect to BVF's increased $ 1.20 per share offer for AVGN.

Stockholders are to vote on BVF's proposal to remove the board of AVGN and elect Biotechnology Value Fund's (BVF) slate of director nominees.

Avigen Inc (NASDAQ: AVGN) has sent a letter sent to its stockholders saying that Glass Lewis, a «leading independent voting advisory service» has reviewed the Biotechnology Value Fund (B...

NEW YORK, March 23 / PRNewswire / — Biotechnology Value Fund, L.P. («BVF») today announced that PROXY Governance, widely recognized as a leading independent proxy advisory firm, has recommended that shareholders vote for all BVF Proposals on the GOLD proxy card for the special meeting of Avigen, Inc. (Nasdaq: AVGN — News) to be held on March 27, 2009.

[Biotechnology Value Fund] believe that AV - 411 is a high risk drug candidate that is best developed (if at all) by a larger company with greater financial resources and a lower cost of capital.

Biotechnology Value Fund originally filed a 13G notice in relation to AVGN, which indicates a passive investment.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock on March 27, 2009 3 Comments»

BVF Acquisition LLC (the «Purchaser»), an affiliate of Biotechnology Value Fund L.P. («BVF»), which has commenced a cash tender offer to purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: AVGN)(«Avigen») for $ 1.00 per share, announced today that it has extended the expiration date for the tender offer to 6:00 p.m., New York City time, on Friday, March 6, 2009.

[Biotechnology Value Fund] believe that the investment community clearly lacks confidence in such a plan, as evidenced by recent reports from stock analysts and by the $ 0.61 per share closing price of [AVGN]'s common stock on October 30, 2008, reflecting only 31 % of [AVGN]'s financial assets as of September 30, 2008.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Stocks, tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock on March 19, 2009 2 Comments»

We cast our proxy votes on - line today in support of Biotechnology Value Fund's (BVF) proposal to remove the board of Avigen Inc (NASDAQ: AVGN).

[Biotechnology Value Fund] informed the Board of Directors that they think that the previously announced plan of spending [AVGN]'s remaining cash on the development of its early - stage pain drug, AV411 as well as [AVGN]'s corporate infrastructure is fundamentally flawed, especially in light of the current environment for raising additional capital.

Posted in Activist Investors, Avigen (NASDAQ: AVGN), Biotechnology Value Fund, Greenbackd Portfolio, Net Cash Stocks, Stocks Tagged Activist investment, Avigen Inc (NASDAQ: AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock Leave a Comment

SAN FRANCISCO, March 27 / PRNewswire / — Biotechnology Value Fund, L.P. («BVF»), today announced that stockholders of Avigen (Nasdaq: AVGN — News) voted overwhelmingly to remove the existing Board of Directors of Avigen and replace them with BVF's nominees.

Avigen Inc (Nasdaq: AVGN) yesterday mailed a letter to stockholders calling on them to reject the proposal to remove AVGN's board being presented to stockholders by Biotechnology Value Fund (BVF).

«At the invitation of the Chairman of [AVGN], [Biotechnology Value Fund] articulated their views regarding the future of the Company in a conference call with the Board of Directors held on October 30, 2008.

Avigen Inc (NASDAQ: AVGN) has sent a letter sent to its stockholders saying that Glass Lewis, a «leading independent voting advisory service» has reviewed the Biotechnology Value Fund (BVF) proposal to remove AVGN's board and has recommended that stockholders vote against the proposal.

Posted in Activist Investors, Biotechnology Value Fund, Neurobiological Technologies Inc (NASDAQ: NTII), Stocks, tagged Activist investment, Biotechnology Value Fund, Liquidating Value, Liquidation Value, Net Cash Stock, Neurobiological Technologies Inc (NASDAQ: NTII) on May 11, 2009 2 Comments»